Loading…
← CockpitCompetitor Analysis › LMAT LeMaitre Vascular, Inc.Open in the cockpit ↗

LeMaitre Vascular, Inc.LMATCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of niche devices for peripheral vascular surgery, including grafts, catheters, valvulotomes and shunts.

Momentum weak 32
Mkt cap
$1.73B
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$23.5M
20-day average traded
Fwd P/E
24.5×
forward earnings
ROIC−WACC
+18.1 pp
WACC 7.4%
Hurdle
-11 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · USD$75.58
1D-0.7%
1W-4.7%
1M-9.4%
3M-8.2%
6M-25.5%
YTD-6.8%
1Y-13.1%
ATR %3.4%
Beta0.61
52w lowhigh36.0% off high

What LeMaitre Vascular does

Maker of niche devices for peripheral vascular surgery, including grafts, catheters, valvulotomes and shunts.

Sells mostly through its own direct sales force to vascular surgeons rather than through distributors, which keeps the relationship and the price. Revenue is spread across many small product lines, and buying small product lines from other companies to push through its salespeople is a regular part of the model.

Products and services

  • Vascular grafts
  • Embolectomy/thrombectomy catheters
  • Valvulotomes & shunts
  • Carotid shunts/patches

Customers

  • Vascular surgeons
  • Hospitals

Where it sits in the supply chain

  • Medical devices
  • Peripheral vascular surgery
  • Vascular grafts, catheters & surgical…

What could go right

  • Peripheral vascular surgery volume growth
  • Niche product portfolio expansion via tuck-in deals

What could go wrong

  • Small addressable market per product
  • Reimbursement/hospital budget pressure

Moat: narrow (brand, distribution, installed base). Long-standing niche brand across many small vascular-surgery product lines with limited direct competition per product.

Headquarters: Burlington, Massachusetts · Founded: 1983 · Employees: 655

Named competitors

LeMaitre Vascular at a glance

Size LeMaitre Vascular (LMAT) is a United States Health Care company (Medical Specialties) with a market value of $1.73B, the 1869th largest of 3,085 United States companies the cockpit tracks. Shares closed at $75.58 on 18 Nov 2026.

Performance Over six months the shares fell 25.5%, against +3.5% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 20 in its peer set.

Growth Revenue grew 11.8% over the last twelve months (peer median +9.6%); the operating margin is 27.7% (peer median 12.7%).

Valuation It trades at 24.5× forward earnings against a peer median of 27.0× (8th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 18.1 points above its cost of capital (7.4% WACC).

Credit LeMaitre Vascular has 1 bond outstanding ($172M).

Short interest Short interest is 7.2% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 102LMAT 76
Six months, rebased to 100: LeMaitre Vascular against the median of its 20 peers (local-currency closes).

LeMaitre Vascular financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$269M$250M$220M$193M$162M
Revenue growth—+14%+14%+20%—
Gross profit$190M$173M$145M$121M$98.7M
EBITDA$85.5M$78.3M$62.0M$46.6M$39.2M
Net income$63.3M$57.7M$44.0M$30.1M$20.6M
Free cash flow$67.0M$74.5M$37.2M$29.5M$22.1M
Capital expenditure$9.21M$6.78M$6.96M$7.26M$3.23M
Total debt$189M$186M$186M$19.1M$16.6M

Quarterly statements and history in the cockpit →

LeMaitre Vascular competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%301363EMBLAXRAYCHEMMKMTSINSP77168086POLYMED10666960BFLY268ASKANMED301087688531VITRLMAT6-month return →1-month return →
Up and to the right = strong over both horizons. LeMaitre Vascular is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×60×301363EMBLAXRAYCHEMMINSP77168086POLYMED1066268A6699SKANMED301087688531VITRLMATRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. LeMaitre Vascular is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%301363EMBLAXRAYCHEMMINSP771610666960268A6699SKAN301087VITRLMATGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. LeMaitre Vascular is the large dot.

LeMaitre Vascular competitors and peer comparison

Head to head with its named competitors (LMAT vs MDT vs GETI-B.ST)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
LeMaitre Vascular LMAT$1.73B-25%+12%28%24.5×2.9%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Getinge GETI-B.ST$7.45B+40%-4%14%21.1×5.0%

How LeMaitre Vascular compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

LeMaitre Vascular against its 20 peers (data as of 18 Nov 2026)
MeasureLMATPeer medianRank in peer set
1-month return-9.4%-4.4%6th lowest of 21
6-month return-25.5%+3.5%4th lowest of 20
Distance from 52-week high-36.0%-23.2%8th lowest of 21
Revenue growth (TTM)+11.8%+9.6%10th highest of 21
Operating margin27.7%12.7%2nd highest of 21
Forward P/E24.5×27.0×8th cheapest of 18
Growth the price implies (Req g, 7 yrs)2.9%13.8%4th least demanding of 14
Growth delivered (Del g)+14.0%+12.7%6th highest of 14
Hurdle (Req g minus delivered)-11.2 pp-0.3 pp4th least demanding of 14
ROIC minus cost of capital+18.1 pp-0.6 pp3rd highest of 21
EV / EBITDA17.9×15.7×7th most expensive of 15
Net debt / EBITDA-2.4×-0.7×3rd least indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
Nakanishi 7716.TJapan$1.78B+7%+17%21%19.0×4.8%+19.7%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Poly Medicure POLYMED.NSIndia$1.79B+14%+25%16%39.9×n/an/a
Shandong Weigao Group Medical Polymer 1066.HKHong Kong$1.82B-8%+7%14%8.2×-12.6%+2.1%
Fukuda Denshi 6960.TJapan$1.84B+4%0%19%15.4×-1.6%-1.0%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
Rigaku 268A.TJapan$1.85B-54%+9%16%23.1×18.3%+14.5%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%

LeMaitre Vascular bonds and credit

LeMaitre Vascular has 1 bond outstanding with $172M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are LeMaitre Vascular's main competitors?
Named competitors: Medtronic (MDT), Getinge AB (GETI-B.ST). The cockpit's measured peer set (industry) also includes Mehow Innovative (301363.SZ), Embla Medical hf (EMBLA.CO), DENTSPLY SIRONA (XRAY), ChemoMetec A/S (CHEMM.CO), Kestra Medical Technologies (KMTS), Inspire Medical Systems (INSP).
Is LeMaitre Vascular expensive compared with its peers?
On forward p/e it trades at 24.5× against a peer median of 27.0×, 8th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has LeMaitre Vascular stock performed?
Over six months to 18 Nov 2026 the shares returned -25.5% against +3.5% for the median peer; over one year -13.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.